Liver Cirrhosis Due to Hepatitis B Virus
Conditions
Brief summary
Liver Cirrhosis is a common pathological consequence of chronic liver disease. Hepatitis B Virus (HBV) is one of most etiologies of liver cirrhosis in China. The effective inhibition of HBV can partially stop or reverse liver fibrosis in patients with chronic Hepatitis and liver cirrhosis due to HBV, and the anti-fibrotic strategy focusing on the regulation of hepatic extracellular matrix is still required and hopefully improve the efficacy of anti-virals for liver fibrotic patients with HBV, especially is necessary for in the patients with advance fibrosis stage ie. liver cirrhosis. Fuzheng Huayu has been found to enhance the degradation of collagens in fibrotic liver and have a good action against liver fibrosis in patients with chronic hepatitis B. However, there are no high quality clinical evidences which can demonstrate if the combination of anti-viral and anti-fibrotic therapy can improve the reversion of liver cirrhosis due to HBV. The primary objective of this study is to establish the safety and efficacy of the combination of Entecavir and Fuzheng Huayu for the reversion of liver fibrosis in patients with liver cirrhosis due to HBV.
Interventions
DRUGEntecavir + Placebo
The subjects will be taking 1 Entecavir tablet per day and 4 Placebo tablets three times a day for 48 weeks.
DRUGEntecavir + Fuzheng Huayu Tablet
The subjects will be taking 1 Entecavir tablet per day and 4 Fuzheng Huayu tablets three times a day for 48 weeks.
Sponsors
Shanghai Zhongshan Hospital
Guangxi Ruikang Hospital
Hubei Hospital of Traditional Chinese Medicine
The First Affiliated Hospital of Hunan University of Traditional Chinese Medicine
Huai'an No. 4 People's Hospital
Ruijin Hospital
Shenzhen Third People's Hospital
Beijing Ditan Hospital
Beijing YouAn Hospital
China-Japan Friendship Hospital
Tongji Hospital
Wenzhou Central Hospital
Jingmen No.1 People's Hospital
Affiliated Hospital of Shandong Univercity of TCM
The Ninth Hospital of Nanchang
The People's Hospital of Ningxia
Fifth Hospital of Shijiazhuang City
The Fifth People's Hospital of Suzhou
The Fifth People's Hospital of Anyang
ShuGuang Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
* More than 6 months history of serum positive HBsAg * Positive HBV-DNA * Age 18-60 * Ishak fibrosis score of the biopsy within 6 months ≥5, no anti-virus or anti-fibrosis drug was taken within 6 months. * Child-Pugh\<7 (Stage A) * The patient or the patient's guardian agrees to participate the trial and sign the informed Consent Form.
Exclusion criteria
* Primary Lamivudine, Adefovir dipivoxil and Entecavir resistance * Decompensated liver cirrhosis * HCC * Liver histology conforming to other chronic liver diseases, such as moderate or severe non-alcoholic fatty liver disease(more than 1/3 steatosis in liver ), chronic hepatitis C, chronic hepatitis D, autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis, inherited metabolic liver disease, drug or toxic induced liver injury, parasitic infections, alcoholic liver disease. * Have psychiatric history or uncontrollable epilepsy patient. * Uncontrollable diabetic patient * History of hemoglobin disease (such as alpha- or beta-thalassemia, sickle cell disease, spherocytosis) or patients with toxic or autoimmune hemolytic anemia. * Severe background disease like chronic respiratory failure, circulatory failure, kidney failure etc. * In situ organ transplantation (such as liver, kidney, lung and heart) or bone marrow transplantation and stem cell transplantation. * Immunocompromised patients: such as HIV infection or take immunosuppressor or glucocorticoid (such as cyclosporin, azathioprine, adrenocortical hormone) within 3 months or chemotherapy drugs (such as cyclophosphamide, ammonia and cancer chemotherapy) and radioactive therapy. * Gestation or lactation period women and women who plan to get pregnant during the study period. * Patient who are allergy to the experimental drug. * Using history of anti-viral or anti-fibrosis drug within 6 months. * Patients who are participating other trials. * Other situation where PI thinks the patient should be excluded.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Degree of liver fibrosis | 48 weeks | The collagen of liver tissue from 48 week post-treatment patients was stained. 3 pathologists read the slides independently and score the slides with Ishak system. If the Ishak score decrease 1 or more than 1 score, then it is recorded as regression. |
Countries
China
Contacts
Primary ContactChenghai Liu, PhD
Outcome results
None listed